Our Pricing

Understanding the Wegovy 2.4mg Click Chart: Your Complete UK Dosing Guide

Navigating the wegovy 2.4mg click chart uk system is essential for patients reaching their maintenance dose. At Cured Pharmacy, we provide genuine UK-licensed Wegovy pens from £79.00, with expert guidance from our clinical team to ensure you're using the click chart correctly throughout your weight management journey.

What Is the Wegovy Click Chart System?

The Wegovy click chart is a dosing mechanism built into each pre-filled pen that allows precise dose selection through an audible and tactile clicking system. Each click corresponds to a specific dose increment, ensuring patients receive exactly the prescribed amount of semaglutide at each weekly injection [1].

The 2.4mg Wegovy pen is designed specifically for patients who have completed the dose escalation schedule and reached the maintenance phase. This pen delivers the full therapeutic dose shown in the STEP clinical trial programme to produce significant weight reduction [1]. Unlike starter pens that contain multiple lower doses, the 2.4mg pen is optimised for long-term maintenance treatment.

Understanding your click chart is crucial for treatment efficacy. Each pen contains four doses of 2.4mg semaglutide, and the click mechanism prevents accidental overdosing whilst ensuring you don't underdose. Our superintendent pharmacist Tarun Kumar regularly advises patients on proper pen technique during their treatment journey.

Wegovy Dose Escalation Schedule: Reaching 2.4mg Safely

The MHRA-approved Wegovy dosing schedule follows a gradual escalation protocol designed to minimise gastrointestinal side effects whilst allowing your body to adapt to semaglutide. The schedule progresses from 0.25mg weekly for four weeks, then 0.5mg, 1mg, 1.7mg, and finally the maintenance dose of 2.4mg [2].

Clinical trials demonstrated that this stepped approach significantly reduces the incidence of nausea and vomiting compared to starting at higher doses. In the STEP 1 trial, 68% of participants achieved at least 10% body weight reduction at the 2.4mg maintenance dose over 68 weeks [1]. Rushing this escalation or skipping doses can compromise both tolerability and clinical outcomes.

Most patients reach the 2.4mg maintenance dose after approximately 16-20 weeks of treatment, subject to individual tolerability and prescriber assessment. Your UK prescriber will evaluate your response at each dose level before authorising progression to the next strength.

When to Switch to the 2.4mg Pen

You should only switch to the 2.4mg click chart pen after successfully completing the 1.7mg dose phase for at least four weeks and receiving prescriber approval. Your clinician will assess your tolerability, weight loss progress, and any side effects before authorising the maintenance dose pen.

At Cured Pharmacy, our UK prescribers conduct thorough follow-up assessments before approving dose escalations. This ensures you're progressing safely through the treatment protocol whilst achieving optimal clinical benefit from semaglutide therapy.

How to Use the Wegovy 2.4mg Click Chart Correctly

Using the 2.4mg click chart requires understanding the pen's dose counter and click mechanism. Before each injection, check the dose counter window shows '2.4' and turn the dose selector until you hear and feel four distinct clicks. Each click represents 0.6mg, so four clicks deliver the full 2.4mg maintenance dose.

Always inspect the solution before injecting — it should be clear and colourless. Attach a new needle for each injection and perform an air shot to ensure the pen is working correctly. Inject subcutaneously into your abdomen, thigh, or upper arm, rotating injection sites weekly to prevent lipodystrophy [2].

Common mistakes include not rotating injection sites, reusing needles, or failing to hold the pen in place for the full six seconds after pressing the dose button. These errors can result in incomplete dosing or injection site reactions. If you're unsure about technique, our pharmacy team at Cured Pharmacy provides detailed patient counselling with every dispensed prescription.

Storage and Handling Requirements

Store unused Wegovy pens in the refrigerator between 2°C and 8°C, away from the freezer compartment. Once in use, pens can be stored at room temperature (below 30°C) for up to 28 days. Always keep the pen cap on when not in use to protect from light.

Never use a pen that has been frozen, even if it has thawed. Freezing can damage the semaglutide molecule and compromise efficacy. Dispose of used pens in a sharps container — never in household waste.

Clinical Evidence for Wegovy 2.4mg Maintenance Dosing

The STEP clinical trial programme established 2.4mg weekly semaglutide as the optimal maintenance dose for chronic weight management. In STEP 1, participants receiving 2.4mg achieved an average 14.9% body weight reduction compared to 2.4% with placebo over 68 weeks [1]. Importantly, 86.4% of participants maintained at least 5% weight loss at this dose.

Long-term data from STEP 5 demonstrated sustained weight reduction over 104 weeks at the 2.4mg maintenance dose, with participants losing an average of 15.2% body weight [3]. This evidence supports 2.4mg as the therapeutic target dose for most patients, though individual responses vary based on metabolic factors and adherence.

The cardiovascular benefits observed in the SELECT trial further validate 2.4mg semaglutide for long-term use. Participants showed a 20% reduction in major adverse cardiovascular events compared to placebo, independent of weight loss magnitude [4]. These findings have strengthened NICE guidance supporting semaglutide for weight management in appropriate patient populations.

Switching from Other Weight Loss Treatments to Wegovy 2.4mg

Patients switching from liraglutide (Saxenda) to semaglutide should begin with the standard Wegovy escalation schedule starting at 0.25mg, not the 2.4mg maintenance dose. Despite both being GLP-1 receptor agonists, the different pharmacokinetic profiles require dose titration to ensure tolerability [2].

If you're switching from oral semaglutide (Rybelsus) to injectable Wegovy, your prescriber will determine the appropriate starting dose based on your current oral dose. Generally, patients on 14mg daily oral semaglutide may start at a higher Wegovy dose than treatment-naïve patients, but this requires individual clinical assessment.

Switching between different semaglutide products for cost reasons requires prescriber approval and may involve temporary dose adjustments. At Cured Pharmacy, our competitive pricing from £79.00 helps patients maintain consistent treatment without switching between products, supporting better long-term adherence and outcomes.

Transitioning from Mounjaro to Wegovy

Patients switching from tirzepatide (Mounjaro) to semaglutide should expect different efficacy profiles, as tirzepatide acts on both GIP and GLP-1 receptors whilst semaglutide targets only GLP-1. Your prescriber will determine whether to start Wegovy at the beginning of the escalation schedule or at a higher dose based on your tirzepatide dose and tolerability.

Allow at least one week washout between stopping tirzepatide and starting semaglutide to minimise overlapping side effects. Your UK prescriber will provide specific guidance based on your treatment history and clinical response.

Cost Comparison: Why Patients Switch to Cured Pharmacy for Wegovy 2.4mg

Wegovy pricing varies significantly across UK online pharmacies, with maintenance dose pens representing a substantial monthly investment for most patients. At Cured Pharmacy, we maintain transparent upfront pricing from £79.00, with costs displayed before you complete your clinical consultation — no hidden fees or surprise charges at checkout.

Our lowest price guarantee ensures you're receiving competitive UK pricing for genuine MHRA-licensed medication. We source directly from licensed UK wholesalers and never compromise on medication authenticity to reduce costs. Every Wegovy pen dispensed by Cured Pharmacy includes full patient information leaflets and access to our pharmacist support line.

Many patients switch to Cured Pharmacy after experiencing higher costs elsewhere. Our streamlined online consultation process takes under three minutes, and our UK-registered prescribers typically review assessments within 24 hours. We offer discreet next-day delivery across the UK, with all packages in plain, unmarked packaging to protect your privacy.

What's Included in Your Wegovy Prescription

Every Wegovy prescription from Cured Pharmacy includes four 2.4mg doses per pen, detailed injection instructions, and access to our clinical support team. We provide pen needles with each prescription and guidance on proper disposal of used sharps.

Your prescription includes follow-up consultation options to monitor progress and manage any side effects. Our superintendent pharmacist Tarun Kumar oversees all dispensing to ensure you receive the correct medication and appropriate clinical support throughout your treatment journey.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://products.mhra.gov.uk/
3. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
4. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and must be prescribed by a UK-registered clinician following appropriate clinical assessment. Individual results may vary and weight loss outcomes depend on multiple factors including diet, exercise, and adherence to the prescribed regimen.